Top

Published in:

01-06-2012 | Position Statement

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Authors: S. E. Inzucchi, R. M. Bergenstal, J. B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. L. Peters, A. Tsapas, R. Wender, D. R. Matthews

Published in: Diabetologia | Issue 6/2012

Excerpt

Glycaemic management in type 2 diabetes mellitus has become increasingly complex and, to some extent, controversial, with a widening array of pharmacological agents now available [1‐5], mounting concerns about their potential adverse effects and new uncertainties regarding the benefits of intensive glycaemic control on macrovascular complications [6‐9]. Many clinicians are therefore perplexed as to the optimal strategies for their patients. As a consequence, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) convened a joint task force to examine the evidence and develop recommendations for anti-hyperglycaemic therapy in non-pregnant adults with type 2 diabetes. Several guideline documents have been developed by members of these two organisations [10] and by other societies and federations [2, 11‐15]. However, an update was deemed necessary because of contemporary information on the benefits/risks of glycaemic control, recent evidence concerning efficacy and safety of several new drug classes [16, 17], the withdrawal/restriction of others and increasing calls for a move towards more patient-centred care [18, 19]. …

Available only for authorised users

Bolen S, Feldman L, Vassy J et al (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147:386–399PubMed

Bergenstal RM, Bailey CJ, Kendall DM (2010) Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Am J Med 123(374):e9–e18PubMed

Nyenwe EA, Jerkins TW, Umpierrez GE, Kitabchi AE (2011) Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 60:1–23PubMedCrossRef

Nolan JJ (2010) Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes. Diabetologia 53:1247–1249PubMedCrossRef

Blonde L (2010) Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. Am J Med 123(3 Suppl):S12–S18PubMedCrossRef

Greenfield S, Billimek J, Pellegrini F et al (2009) Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med 151:854–860PubMed

Matthews DR, Tsapas A (2008) Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. Diab Vasc Dis Res 5:216–218PubMedCrossRef

Skyler JS, Bergenstal R, Bonow RO et al (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32:187–192PubMedCrossRef

Yudkin JS, Richter B, Gale EA (2011) Intensified glucose control in type 2 diabetes—whose agenda? Lancet 377:1220–1222PubMedCrossRef

10.

Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17–30PubMedCrossRef

11.

IDF Clinical Guidelines Task Force (2005) Global guideline for type 2 diabetes. International Diabetes Federation, Brussels

12.

Rodbard HW, Jellinger PS, Davidson JA et al (2009) Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 15:540–559PubMed

13.

Berard LD, Booth G, Capes S, Quinn K, Woo V (2008) Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes 32:S1–S201

14.

NICE (2009) Type 2 diabetes: the management of type 2 diabetes: NICE Clinical Guideline 87: National Institute for Health and Clinical Excellence

15.

Home P, Mant J, Diaz J, Turner C (2008) Management of type 2 diabetes: summary of updated NICE guidance. BMJ 336:1306–1308PubMedCrossRef

16.

Davidson JA (2010) Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. Mayo Clin Proc 85:S27–S37PubMedCrossRef

17.

DeFronzo RA (2010) Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med 123:S38–S48PubMedCrossRef

18.

Murad MH, Shah ND, van Houten HK et al (2011) Individuals with diabetes preferred that future trials use patient-important outcomes and provide pragmatic inferences. J Clin Epidemiol 64:743–748PubMedCrossRef

19.

Glasgow RE, Peeples M, Skovlund SE (2008) Where is the patient in diabetes performance measures? The case for including patient-centered and self-management measures. Diabetes Care 31:1046–1050PubMedCrossRef

20.

Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S (2011) Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 154:554–559PubMed

21.

Mullan RJ, Montori VM, Shah ND et al (2009) The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med 169:1560–1568PubMedCrossRef

22.

Schernthaner G, Barnett AH, Betteridge DJ et al (2010) Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 53:1258–1269PubMedCrossRef

23.

Gandhi GY, Murad MH, Fujiyoshi A et al (2008) Patient-important outcomes in registered diabetes trials. JAMA 299:2543–2549PubMedCrossRef

24.

Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter JI (2010) Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab 95:1566–1574PubMedCrossRef

25.

Committee on Quality of Health Care in America: Institute of Medicine (2001) Crossing the quality chasm: a new health system for the 21st century. The National Academies Press, Washington

26.

Guyatt GH, Haynes RB, Jaeschke RZ, Cook DJ, Green L, Naylor CD et al (2000) Users’ Guides to the Medical Literature: XXV. Evidence-based medicine: principles for applying the Users’ Guides to patient care. Evidence-Based Medicine Working Group. JAMA 284:1290–1296PubMedCrossRef

27.

Tsapas A, Matthews DR (2008) N of 1 trials in diabetes: making individual therapeutic decisions. Diabetologia 51:921–925PubMedCrossRef

28.

Shah ND, Mullan RJ, Breslin M, Yawn BP, Ting HH, Montori VM (2010) Translating comparative effectiveness into practice: the case of diabetes medications. Med Care 48:S153–S158PubMedCrossRef

29.

Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412PubMedCrossRef

30.

Turner RC, Holman RR, Cull CA et al (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837–853CrossRef

31.

UKPDS Group (1991) UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia 34:877–890CrossRef

32.

Turner RC, Holman RR, Cull CA et al (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854–865CrossRef

33.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589PubMedCrossRef

34.

Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559PubMedCrossRef

35.

Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572PubMedCrossRef

36.

Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:2288–2298, Erratum 52:2470PubMedCrossRef

37.

Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA (2005) Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 90:493–500PubMedCrossRef

38.

Nauck MA (2011) Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 124:S3–S18PubMedCrossRef

39.

Ferrannini E (2010) The stunned beta cell: a brief history. Cell Metab 11:349–352PubMedCrossRef

40.

Nauck MA (2009) Unraveling the science of incretin biology. Am J Med 122:S3–S10PubMedCrossRef

41.

Groop LC, Ferrannini E (1993) Insulin action and substrate competition. Baillieres Clin Endocrinol Metab 7:1007–1032PubMedCrossRef

42.

ADA (2011) Standards of medical care in diabetes–2011. Diabetes Care 34(Suppl 1):S11–S61

43.

Akalin S, Berntorp K, Ceriello A et al (2009) Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. Int J Clin Pract 63:1421–1425PubMedCrossRef

44.

Lee SJ, Eng C (2011) Goals of glycemic control in frail older patients with diabetes. JAMA 305:1350–1351PubMedCrossRef

45.

Ahmed MH, Byrne CD (2009) Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 11:188–195PubMedCrossRef

46.

May C, Montori VM, Mair FS (2009) We need minimally disruptive medicine. BMJ 339:b2803PubMedCrossRef

47.

Anderson JW, Kendall CW, Jenkins DJ (2003) Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 22:331–339PubMed

48.

Klein S, Sheard NF, Pi-Sunyer X et al (2004) Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 27:2067–2073PubMedCrossRef

49.

Bantle JP, Wylie-Rosett J, Albright AL et al (2008) Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 31(Suppl 1):S61–S78PubMed

50.

Elmer PJ, Obarzanek E, Vollmer WM et al (2006) Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 144:485–495PubMed

51.

Gordon NF, Salmon RD, Franklin BA et al (2004) Effectiveness of therapeutic lifestyle changes in patients with hypertension, hyperlipidemia, and/or hyperglycemia. Am J Cardiol 94:1558–1561PubMedCrossRef

52.

Wing RR, Tate DF, Gorin AA, Raynor HA, Fava JL (2006) A self-regulation program for maintenance of weight loss. N Engl J Med 355:1563–1571PubMedCrossRef

53.

Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ (2001) Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 286:1218–1227PubMedCrossRef

54.

Bailey CJ, Turner RC (1996) Metformin. N Engl J Med 334:574–579PubMedCrossRef

55.

Lamanna C, Monami M, Marchionni N, Mannucci E (2011) Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 13:221–228PubMedCrossRef

56.

Bryan J, Crane A, Vila-Carriles WH, Babenko AP, Aguilar-Bryan L (2005) Insulin secretagogues, sulfonylurea receptors and K(ATP) channels. Curr Pharm Des 11:2699–2716PubMedCrossRef

57.

Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443PubMedCrossRef

58.

Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA (2005) PRESERVE-β: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 28:2093–2099PubMedCrossRef

59.

Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351:1106–1118PubMedCrossRef

60.

Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289PubMedCrossRef

61.

Nissen SE, Wolski K (2010) Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 170:1191–1201PubMedCrossRef

62.

Lewis JD, Ferrara A, Peng T et al (2011) Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34:916–922PubMedCrossRef

63.

Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696–1705PubMedCrossRef

64.

Deacon CF (2011) Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 13:7–18PubMedCrossRef

65.

Van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, de Grauw WJ (2006) Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev. Issue 4. Art. no.: CD005061. doi:10.1002/14651858.CD005061.pub2

66.

Fonseca VA, Handelsman Y, Staels B (2010) Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab 12:384–392PubMedCrossRef

67.

Defronzo RA (2011) Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 34:789–794PubMedCrossRef

68.

Singh-Franco D, Robles G, Gazze D (2007) Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 29:535–562PubMedCrossRef

69.

Peters A (2010) Incretin-based therapies: review of current clinical trial data. Am J Med 123:S28–S37PubMedCrossRef

70.

Bennett WL, Maruthur NM, Singh S et al (2011) Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 154:602–613PubMed

71.

Jabbour S (2008) Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both? Int J Clin Pract 62:845–847PubMedCrossRef

72.

Bergenstal RM, Johnson M, Powers MA et al (2008) Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 31:1305–1310PubMedCrossRef

73.

Cryer PE (2002) Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 45:937–948PubMedCrossRef

74.

Holman RR, Farmer AJ, Davies MJ et al (2009) Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 361:1736–1747PubMedCrossRef

75.

Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P (2006) A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29:1269–1274PubMedCrossRef

76.

Riddle MC (2006) The Treat-to-Target Trial and related studies. Endocr Pract 12(Suppl 1):71–79PubMed

77.

Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G (2008) A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 51:408–416PubMedCrossRef

78.

Simonson GD, Cuddihy RM, Reader D, Bergenstal RM (2011) International Diabetes Center treatment of type 2 diabetes glucose algorithm. Diabetes Management 1:175–189CrossRef

79.

Gross JL, Kramer CK, Leitao CB et al (2011) Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 154:672–679PubMed

80.

Karagiannis T, Paschos P, Paletas P, Matthews DR, Tsapas A (2012) Dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 344:e1369PubMedCrossRef

81.

Cryer PE (2007) Severe iatrogenic hypoglycemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 3:4–5PubMedCrossRef

82.

Loke YK, Kwok CS, Singh S (2011) Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 342:d1309PubMedCrossRef

83.

Kendall DM, Riddle MC, Rosenstock J et al (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083–1091PubMedCrossRef

84.

Zinman B, Gerich J, Buse JB et al (2009) Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32:1224–1230PubMedCrossRef

85.

Roberts VL, Stewart J, Issa M, Lake B, Melis R (2005) Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 27:1535–1547PubMedCrossRef

86.

Bell DS, Dharmalingam M, Kumar S, Sawakhande RB (2011) Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II). Diabetes Obes Metab 13:800–805PubMedCrossRef

87.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G (2006) Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29:554–559PubMedCrossRef

88.

Yki-Jarvinen H, Juurinen L, Alvarsson M et al (2007) Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 30:1364–1369PubMedCrossRef

89.

Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R (2005) Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 28:1282–1288PubMedCrossRef

90.

Garber AJ (2009) The importance of titrating starting insulin regimens in patients with type 2 diabetes. Diabetes Obes Metab 11(Suppl 5):10–13PubMedCrossRef

91.

Owens DR, Luzio SD, Sert-Langeron C, Riddle MC (2011) Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ study. Diabetes Obes Metab 13:1020–1027PubMedCrossRef

92.

Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P (2011) A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract 17:395–403PubMedCrossRef

93.

Raccah D (2008) Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus. Diabetes Obes Metab 10(Suppl 2):76–82PubMedCrossRef

94.

Ilag LL, Kerr L, Malone JK, Tan MH (2007) Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther 29:1254–1270CrossRef

95.

Aviles-Santa L, Sinding J, Raskin P (1999) Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 131:182–188PubMed

96.

Strowig SM, Raskin P (2005) Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. Diabetes Obes Metab 7:633–641PubMedCrossRef

97.

Buse JB (2011) Type 2 diabetes mellitus in 2010: individualizing treatment targets in diabetes care. Nat Rev Endocrinol 7:67–68PubMedCrossRef

98.

Vilsboll T, Rosenstock J, Yki-Jarvinen H et al (2010) Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 12:167–177PubMedCrossRef

99.

Del Prato S, Heine RJ, Keilson L, Guitard C, Shen SG, Emmons RP (2003) Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. Diabetes Care 26:2075–2080PubMedCrossRef

100.

Booth GL, Kapral MK, Fung K, Tu JV (2006) Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 368:29–36PubMedCrossRef

101.

Nelson JM, Dufraux K, Cook PF (2007) The relationship between glycemic control and falls in older adults. J Am Geriatr Soc 55:2041–2044PubMedCrossRef

102.

Sluik D, Boeing H, Montonen J et al (2011) Associations between general and abdominal adiposity and mortality in individuals with diabetes mellitus. Am J Epidemiol 174:22–34PubMedCrossRef

103.

Unick JL, Beavers D, Jakicic JM et al (2011) Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes Care 34:2152–2157PubMedCrossRef

104.

Krentz AJ, Bailey CJ (2005) Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 65:385–411PubMedCrossRef

105.

Buchwald H, Estok R, Fahrbach K et al (2009) Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 122:248–256, e5PubMedCrossRef

106.

Davis TM, Wright AD, Mehta ZM et al (2005) Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 48:695–702PubMedCrossRef

107.

Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB (2003) The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163:427–436PubMedCrossRef

108.

Chen KW, Boyko EJ, Bergstrom RW et al (1995) Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men. Diabetes Care 18:747–753PubMedCrossRef

109.

Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3–19PubMedCrossRef

110.

Malecki MT, Mlynarski W (2008) Monogenic diabetes: implications for therapy of rare types of disease. Diabetes Obes Metab 10:607–616PubMedCrossRef

111.

Nordin C (2010) The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 53:1552–1561PubMedCrossRef

112.

Riveline JP, Danchin N, Ledru F, Varroud-Vial M, Charpentier G (2003) Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 29:207–222PubMedCrossRef

113.

Sulistio M, Carothers C, Mangat M, Lujan M, Oliveros R, Chilton R (2009) GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects. Curr Atheroscler Rep 11:93–99PubMedCrossRef

114.

Hanefeld M, Schaper F (2008) Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther 6:153–163PubMedCrossRef

115.

Gaziano JM, Cincotta AH, O’Connor CM, Ezrokhi M, Rutty D, Ma ZJ et al (2010) Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 33:1503–1508PubMedCrossRef

116.

Masoudi FA, Inzucchi SE (2007) Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol 99:113B–132BPubMedCrossRef

117.

Lago RM, Singh PP, Nesto RW (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370:1129–1136PubMedCrossRef

118.

Chaggar PS, Shaw SM, Williams SG (2009) Review article: thiazolidinediones and heart failure. Diab Vasc Dis Res 6:146–152PubMedCrossRef

119.

Tahrani AA, Varughese GI, Scarpello JH, Hanna FW (2007) Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ 335:508–512PubMedCrossRef

120.

Inzucchi SE, McGuire DK (2008) New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation 117:574–584PubMedCrossRef

121.

Huang ES, Liu JY, Moffet HH, John PM, Karter AJ (2011) Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care 34:1329–1336PubMedCrossRef

122.

Koro CE, Lee BH, Bowlin SJ (2009) Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 31:2608–2617PubMedCrossRef

123.

Holstein A, Stumvoll M (2005) Contraindications can damage your health–is metformin a case in point? Diabetologia 48:2454–2459PubMedCrossRef

124.

Lipska KJ, Bailey CJ, Inzucchi SE (2011) Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 34:1431–1437PubMedCrossRef

125.

Nye HJ, Herrington WG (2011) Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 118:c380–c383PubMedCrossRef

126.

Ong JP, Younossi ZM (2007) Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 11:1–16, viiPubMedCrossRef

127.

Musso G, Gambino R, Cassader M, Pagano G (2011) Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43:617–649PubMedCrossRef

128.

Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ (2006) Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 26:1015–1017PubMedCrossRef

129.

Gerstein HC, Miller ME, Genuth S et al (2011) Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364:818–828PubMedCrossRef

130.

Bonds DE, Miller ME, Bergenstal RM et al (2010) The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340:b4909PubMedCrossRef

131.

Riddle MC (2010) Counterpoint: intensive glucose control and mortality in ACCORD–still looking for clues. Diabetes Care 33:2722–2724PubMedCrossRef

132.

Berlie HD, Garwood CL (2010) Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly. Ann Pharmacother 44:712–717PubMedCrossRef

133.

Rodbard D (2010) The combinatorics of medications precludes evidence-based algorithms for therapy. Diabetologia 53:2456–2457PubMedCrossRef

134.

Chiasson JL, Josse RG, Gomis R et al (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486–494PubMedCrossRef

Title: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Authors: S. E. Inzucchi
R. M. Bergenstal
J. B. Buse
M. Diamant
E. Ferrannini
M. Nauck
A. L. Peters
A. Tsapas
R. Wender
D. R. Matthews
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 6/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-012-2534-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2012

Involvement of the RNA-binding protein ARE/poly(U)-binding factor 1 (AUF1) in the cytotoxic effects of proinflammatory cytokines on pancreatic beta cells

Endothelial dysfunction in type 2 diabetes

Is ARE/poly(U)-binding factor 1 (AUF1) a new player in cytokine-mediated beta cell apoptosis?

Carbohydrate response element-binding protein (ChREBP) plays a pivotal role in beta cell glucotoxicity

Soluble CD163: a biomarker linking macrophages and insulin resistance

Type 2 diabetes mellitus worsens arterial stiffness in hypertensive patients through endothelial dysfunction

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page